Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study (CHRONOS)

A Non-interventional multiCenter Observational Study to Evaluate tHe Effectiveness and Patient-Reported Outcomes of Ofatumumab (Kesimpta®) in patieNts With Relapsing Multiple sclerOsis Treated in Routine Care Settings in Greece (CHRONOS)

This study is a single-country, non-interventional, multicenter, observational study, mainly based on primary data collection to assess the effect of ofatumumab on clinical parameters of Multiple Sclerosis (MS) in a routine medical care setting, as compared to the standard of care (SoC) arm of a closely monitored phase-IIIb study (STHENOS, which includes glatiramer acetate, interferons, teriflunomide, or dimethyl fumarate)

Study Overview

• Status: Recruiting
• Conditions: Relapsing Multiple Sclerosis (RMS)
• Intervention / Treatment: Other: Ofatumumab

Detailed Description

Primary data from MS adult patients who initiate ofatumumab early in their disease course will be collected over a period of two years, and will be compared to the ofatumumab and Standard of Care (SoC) arms of the STHENOS trial, a closely monitored phase-IIIb trial. Eligible patients are those with Relapsing Multiple Sclerosis (RMS) diagnosis, with 1st MS symptom within 5 years prior to ofatumumab's initiation and on treatment with ofatumumab for at least 3 months, but not longer than 6 months prior to inclusion in the study. The overall study duration is expected to be 48 months, including a recruitment period and a per-patient observation period of 24 months each. Follow-up visit frequency will be determined by the treating physician, however study-related data will be collected at study enrollment and at 6-, 12-, 18-, and 24-month data collection timepoints post with an allowable time window of ±1 month for all data collection timepoints. NEDA-3 status, MS Relapse, EDSS, MRI, PROs questionnaires, MSIS-29, SDMT, Adherence and persistence, AEs will be assessed during the study.

• Study Type: Observational
• Enrollment (Estimated): 160

Contacts and Locations

• Study Contact: Name: Novartis Pharmaceuticals; Phone Number: +41613241111; Email: novartis.email@novartis.com
• Study Contact Backup: Name: Novartis Pharmaceuticals

Study Locations

• Greece
  • Alexandroupoli, Greece, 681 00
    • Recruiting
    • Novartis Investigative Site
  • Athens, Greece, 115 27
    • Recruiting
    • Novartis Investigative Site
  • Athens, Greece, 115 28
    • Recruiting
    • Novartis Investigative Site
  • Athens, Greece, 115 21
    • Recruiting
    • Novartis Investigative Site
  • Athens, Greece, 115 25
    • Recruiting
    • Novartis Investigative Site
  • Athens, Greece, 145 61
    • Active, not recruiting
    • Novartis Investigative Site
  • Athens, Greece, 185 47
    • Recruiting
    • Novartis Investigative Site
  • Chaïdári, Greece, 124 62
    • Recruiting
    • Novartis Investigative Site
  • Crete Heraklion, Greece, 714 09
    • Recruiting
    • Novartis Investigative Site
  • Ioannina, Greece, 455 00
    • Recruiting
    • Novartis Investigative Site
  • Larissa, Greece, 411 10
    • Recruiting
    • Novartis Investigative Site
  • Pátrai, Greece, 265 04
    • Recruiting
    • Novartis Investigative Site
  • Thessaloniki, Greece, 53246
    • Recruiting
    • Novartis Investigative Site
  • Thessaloniki, Greece, GR 54636
    • Recruiting
    • Novartis Investigative Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Adult patients with RMS who have initiated treatment with ofatumumab early in their disease course. Patients will have been administered ofatumumab (Kesimpta®) three to six months prior to informed consent (IC) and will continue to be treated according to the local product's prescribing information and routine medical practice in terms of visit frequency and type of assessments performed, after enrolment.

Description

Inclusion Criteria:

1. Written IC must be obtained before participating in the study.
2. Patients with diagnosis of RMS per McDonald Criteria (2017) and <5 years since first MS symptom prior to initiation of ofatumumab.
3. Patients who have been on treatment with ofatumumab for at least 3 months, but not longer than 6 months prior to inclusion in the study.
4. Ofatumumab treatment in line with the European Product Information of Kesimpta (i.e., adult patients with relapsing forms of MS with active disease defined by clinical or imaging features).

5. Patients with at least one available brain MRI scan performed at least 3 months after ofatumumab initiation OR for whom the physician (as per her/his routine practice and independently of his/her decision to include the patient in the current study) plans to perform such scanning within 31 days after patient's inclusion in the study.

   Notes: This MRI scan can be either brain gadolinium enhanced (Gd+) or not. In case it is not gadolinium enhanced, the most recent MRI prior to ofatumumab treatment should be brain gadolinium enhanced, for relevant comparison and identification of new lesions. This MRI scan will serve as the index reference assessment for the evaluation of NEDA-3 radiological component and shall not have been performed within 30 days after the termination of steroid therapy.

6. Patients willing and able to complete the assessments, including PRO questionnaires, as per physicians' clinical practice and as outlined in this study.

Exclusion Criteria:

1. Use of investigational drugs during the study, OR between ofatumumab initiation and inclusion into the study, OR within 3 months before ofatumumab initiation, OR within 5 half-lives of investigational drug before ofatumumab initiation, OR until the expected pharmacodynamic effect has returned to baseline, whichever is longer.
2. Currently pregnant (or intention to become pregnant within the study period), breastfeeding or lactating women.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
CHRONOS cohort; Patients prescribed with ofatumumab in a real world setting	Other: Ofatumumab; This is an observational study. There is no treatment allocation. The decision to initiate ofatumumab will be based solely on clinical judgement.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of patients with no evidence of disease activity (NEDA-3) compared to SoC arm of STHENOS	Achievement of NEDA-3 status (no evidence of disease activity based on three components): A) No confirmed multiple sclerosis clinical relapse B) No new MRI brain activity (no new or enlarging T2 lesions, no gadolinium positive (Gd+) T1 lesions) C) No six-month confirmed disability worsening (6m-CDW).	12 months post-enrollment for Chronos cohort and 15 months post-baseline for SoC arm of Sthenos

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of patients achieving NEDA-3 status compared to Ofatumumab arm of STHENOS	Achievement of NEDA-3 status (no evidence of disease activity based on three components): A) No confirmed multiple sclerosis clinical relapse B) No new MRI brain activity (no new or enlarging T2 lesions, no gadolinium positive (Gd+) T1 lesions) C) No six-month confirmed disability worsening (6m-CDW).	12 months post-enrollment for Chronos cohort and 15 months post-baseline for ofatumumab arm of Sthenos
Proportion of patients achieving each individual component of NEDA-3 compared to Ofatumumab arm of STHENOS	Achievement of NEDA-3 status and individual NEDA-3 components: A) Proportion of patients with no confirmed multiple sclerosis clinical relapse B) Proportion of patients with no new or enlarging T2 lesions, no gadolinium positive (Gd+) T1 lesions C) Proportion of patients with no six-month confirmed disability worsening (6m-CDW).	12 months post-enrollment for Chronos cohort and 15 months post-baseline for ofatumumab arm of Sthenos
Proportion of patients achieving NEDA-3 status (no comparator)	Achievement of NEDA-3 status (no evidence of disease activity based on three components): A) No confirmed multiple sclerosis clinical relapse B) No new MRI brain activity (no new or enlarging T2 lesions, no gadolinium positive (Gd+) T1 lesions) C) No six-month confirmed disability worsening (6m-CDW).	18 months post-enrollment
Proportion of patients achieving each individual component of NEDA-3 (no comparator)	Achievement of NEDA-3 status and individual NEDA-3 components: A) Proportion of patients with no confirmed multiple sclerosis clinical relapse B) Proportion of patients with no new or enlarging T2 lesions, no gadolinium positive (Gd+) T1 lesions C) Proportion of patients with no six-month confirmed disability worsening (6m-CDW).	18 months post-enrollment
Proportion of patients free of 6m-RAW and 6m-PIRA - no comparator	Proportion of patients free of 6-month confirmed relapse-associated worsening (6m-RAW); Proportion of patients free of 6-month confirmed progression independent of relapse activity (6m-PIRA); Proportion of patients free of both 6m-RAW and 6m-PIRA	12 and 18 months post-enrollment
Change in MSIS-29 impact score from enrollment.	Change in MSIS-29 physical impact score from enrollment.; Change in MSIS-29 psychological impact score from enrollment. The MSIS-29 is a brief self-reported measurement of the impact of multiple sclerosis on patients' quality of life (measuring 20 items for physical & 9 items for mental/psychological health), where high scores indicate worse health.	Enrollment, 12, 18 and 24 months post-enrollment
Persistence and treatment discontinuation	Proportion of patients remaining on treatment with ofatumumab and proportion of patients permanently discontinuing ofatumumab during the study.	24 months post-enrollment
Time from the start of ofatumumab to all-cause treatment discontinuation	Time from the start of ofatumumab to all-cause treatment discontinuation	24 months post-enrollment

Collaborators and Investigators

• Sponsor: Novartis Pharmaceuticals
• Investigators: Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Study record dates

Study Major Dates

• Study Start (Actual): December 10, 2024
• Primary Completion (Estimated): December 30, 2028
• Study Completion (Estimated): December 30, 2028

Study Registration Dates

• First Submitted: June 27, 2024
• First Submitted That Met QC Criteria: June 27, 2024
• First Posted (Actual): July 5, 2024

Study Record Updates

• Last Update Posted (Actual): December 24, 2025
• Last Update Submitted That Met QC Criteria: December 23, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Keywords: Ofatumumab; Kesimpta; NIS; Greece; RMS; Relapsing Multiple Sclerosis (RMS)
• Additional Relevant MeSH Terms: Nervous System Diseases; Pathologic Processes; Autoimmune Diseases; Immune System Diseases; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Demyelinating Diseases; Multiple Sclerosis; Sclerosis; Antineoplastic Agents; ofatumumab
• Other Study ID Numbers: COMB157GGR01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO